专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

WO2012073017A1 SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES 审中-公开
标题翻译：作为FGFR激酶抑制剂治疗癌症疾病的替代苯并噻嗪衍生物
公开(公告)号：WO2012073017A1
公开(公告)日：2012-06-07
申请号：PCT/GB2011/052356
申请日：2011-11-29
申请人： ASTEX THERAPEUTICS LIMITED , SAXTY, Gordon , MURRAY, Christopher William , BERDINI, Valerio , BESONG, Gilbert Ebai , HAMLETT, Christopher Charles Frederick , WOODHEAD, Steven John , LIGNY, Yannick Aimé Eddy , ANGIBAUD, Patrick René
发明人： SAXTY, Gordon , MURRAY, Christopher William , BERDINI, Valerio , BESONG, Gilbert Ebai , HAMLETT, Christopher Charles Frederick , WOODHEAD, Steven John , LIGNY, Yannick Aimé Eddy , ANGIBAUD, Patrick René
IPC分类号： C07D403/04 , A61K31/502 , A61P35/00
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14
摘要： The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
摘要翻译：本发明涉及新的喹喔啉衍生物化合物，包含所述化合物的药物组合物，用于制备所述化合物的方法和所述化合物在治疗疾病中的用途。癌症。

3. 发明申请

WO2008110846A2 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2008110846A2
公开(公告)日：2008-09-18
申请号：PCT/GB2008/050180
申请日：2008-03-14
申请人： ASTEX THERAPEUTICS LIMITED , THE INSTITUTE OF CANCER RESEARCH:ROYAL CANCER HOSPITAL , CANCER RESEARCH TECHNOLOGY LIMITED , ASTRAZENECA AB , WOODHEAD, Steven John , REES, David Charles , FREDERICKSON, Martyn , GRIMSHAW, Kyla Merriom
发明人： WOODHEAD, Steven John , REES, David Charles , FREDERICKSON, Martyn , GRIMSHAW, Kyla Merriom
IPC分类号： A61K31/415 , C07D231/12 , C07D301/00 , A61P35/00
CPC分类号： A61K31/415 , C07C215/32 , C07C247/10 , C07C309/30 , C07D231/12 , A61K2300/00
摘要： The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)- 1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)- phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H- pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates.
摘要翻译：本发明提供了包含（S）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇的组合物，其中组合物基本上不含的（R）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇或该组合物含有（S）和（（S）对映异构体占优势。还提供了制备（S）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇的方法，新工艺中间体和制备新工艺中间体的方法。

4. 发明申请

WO2012069088A1 METHOD AND DEVICE FOR BUFFERING DATA FOR MULTIPLEXING 审中-公开
标题翻译：用于缓冲多路复用数据的方法和装置
公开(公告)号：WO2012069088A1
公开(公告)日：2012-05-31
申请号：PCT/EP2010/068296
申请日：2010-11-26
申请人： TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) , BENNETT, Jeremy , WOODHEAD, Steven John
发明人： BENNETT, Jeremy , WOODHEAD, Steven John
IPC分类号： H04L29/06 , H04N7/24 , H04L12/56
CPC分类号： H04N21/23611 , H04L47/22 , H04L47/2408 , H04L47/29 , H04L47/30 , H04L65/602 , H04N21/23406 , H04N21/23614 , H04N21/23655
摘要： The invention relates to a method and device for buffering data for multiplexing. The invention also relates to a method of multiplexing and to a multiplexer arrangement using the method and device for buffering data for multiplexing. In one embodiment the invention can be applied to the buffering of non-traffic data, such as firmware updates or other supplementary information, before multiplexing the non-traffic data with traffic data, such as television data of television channels, to form a satellite broadcast channel. In embodiments of the invention, non-traffic data for multiplexing is buffered and then read out again for multiplexing at a rate which is a function of buffer fullness. The non-traffic data may be multiplexed with at least one traffic data channel. A multiplexer can view the non-traffic data channel as another multiplexing input and can allocate the available bit rate between the traffic data channels and the non-traffic data accordingly.
摘要翻译：本发明涉及用于缓冲多路复用数据的方法和装置。本发明还涉及使用用于缓冲用于复用的数据的方法和装置的复用方法和多路复用器装置。在一个实施例中，在将非业务数据与诸如电视频道的电视数据的业务数据复用之前，本发明可以应用于非业务数据的缓冲，例如固件更新或其他补充信息，以形成卫星广播渠道。在本发明的实施例中，用于多路复用的非业务数据被缓冲，然后再次读出以以缓冲器充满度的函数的复用。非业务数据可以与至少一个业务数据信道多路复用。多路复用器可以将非业务数据信道视为另一复用输入，并且可以相应地在业务数据信道和非业务数据之间分配可用比特率。

5. 发明申请

WO2016057338A1 HETEROARYLAMIDE INHIBITORS OF TBK1 审中-公开
标题翻译： TBK1的异烟肼抑制剂
公开(公告)号：WO2016057338A1
公开(公告)日：2016-04-14
申请号：PCT/US2015/053801
申请日：2015-10-02
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , BIGI, Simone , KEUNG, Walter , SWANN, Steve , VU, Phong H. , WOODHEAD, Steven John , GANGLOFF, Anthony R.
发明人： BIGI, Simone , KEUNG, Walter , SWANN, Steve , VU, Phong H. , WOODHEAD, Steven John , GANGLOFF, Anthony R.
IPC分类号： C07D401/04 , C07D403/12 , C07D401/14 , C07D413/14 , C07D241/20 , C07D491/10 , A61K31/497 , A61P37/00 , A61P29/00 , A61P35/00 , A61P27/00 , A61P19/00 , A61P3/00 , A61P13/00 , A61P17/00 , A61P1/00
CPC分类号： C07D401/04 , A61K31/497 , C07D241/20 , C07D401/00 , C07D401/14 , C07D403/12 , C07D413/14 , C07D491/10
摘要： Disclosed are compounds of formula (1): which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.
摘要翻译：公开了式（1）的化合物：其可用作TBK1的抑制剂。还公开了含有化合物的药物组合物，用于治疗与TBK1相关的病症的方法，以及用于制备化合物及其中间体的方法。

6. 发明申请

WO2013061081A1 ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES 审中-公开
标题翻译：抗生素受体拮抗剂受FGFR激酶抑制作用
公开(公告)号：WO2013061081A1
公开(公告)日：2013-05-02
申请号：PCT/GB2012/052673
申请日：2012-10-26
申请人： ASTEX THERAPEUTICS LIMITED
发明人： WOODHEAD, Steven John , MURRAY, Christopher William , BERDINI, Valerio , SAXTY, Gordon , BESONG, Gilbert, Ebai , MEERPOEL, Lieven , QUEROLLE, Olivier Alexis Georges , PONCELET, Virginie Sophie
IPC分类号： C07D241/42 , C07D241/44 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D407/04 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12
CPC分类号： A61K31/498 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D241/42 , C07D241/44 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/14 , C07D407/04 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D471/04
摘要： The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
摘要翻译：本发明涉及新的喹喔啉衍生物化合物，包含所述化合物的药物组合物，用于制备所述化合物的方法和所述化合物在治疗疾病中的用途。癌症。

7. 发明申请

WO2013061074A1 QUINOLINES AS FGFR KINASE MODULATORS 审中-公开
标题翻译：喹诺酮作为FGFR激酶调节剂
公开(公告)号：WO2013061074A1
公开(公告)日：2013-05-02
申请号：PCT/GB2012/052666
申请日：2012-10-26
申请人： ASTEX THERAPEUTICS LIMITED
发明人： BERDINI, Valerio , ANGIBAUD, Patrick René , WOODHEAD, Steven John , SAXTY, Gordon
IPC分类号： C07D215/38 , C07D401/04 , C07D401/14 , C07D407/14 , C07D413/14 , A61K31/4709 , A61K31/47 , A61P35/00
CPC分类号： A61K31/4709 , A61K31/47 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D215/38 , C07D401/04 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/14
摘要： The invention relates to new quinoline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. Formula (I)
摘要翻译：本发明涉及式（I）的新的喹啉衍生物化合物，包含所述化合物的药物组合物，所述化合物的制备方法以及所述化合物在治疗疾病中的用途。癌症。式（I）

8. 发明公开

EP2134339A2 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES 有权
标题翻译： COMPOSITIONS CONTAINING（S）-2-氨基-1-（4-氯苯基）-1- [4-（1H-吡唑-4-基）苯基]乙醇可用作蛋白激酶的调节剂
公开(公告)号：EP2134339A2
公开(公告)日：2009-12-23
申请号：EP08719025.2
申请日：2008-03-14
申请人： Astex Therapeutics Limited , The Institute of Cancer Research : The Royal Cancer Hospital , Cancer Research Technology Limited
发明人： WOODHEAD, Steven John , REES, David Charles , FREDERICKSON, Martyn , GRIMSHAW, Kyla Merriom
IPC分类号： A61K31/415 , C07D231/12 , C07D301/00 , A61P35/00
CPC分类号： A61K31/415 , C07C215/32 , C07C247/10 , C07C309/30 , C07D231/12 , A61K2300/00
摘要： The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)- 1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)- phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H- pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates.

9. 发明公开

EP1814552A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS 审中-公开
标题翻译：化合物用于治疗由蛋白激酶介导的疾病
公开(公告)号：EP1814552A2
公开(公告)日：2007-08-08
申请号：EP05801609.8
申请日：2005-11-09
申请人： Astex Therapeutics Limited , The Institute of Cancer Research : The Royal Cancer Hospital , Cancer Research Technology Limited
发明人： BERDINI, Valerio , BOYLE, Robert George , SAXTY, Gordon , VERDONK, Marinus Leendert , WOODHEAD, Steven John , WYATT, Paul Graham , SORE, Hannah Fiona , WALKER, David Winter , CALDWELL, John , COLLINS, Ian
IPC分类号： A61K31/505 , A61P35/00 , C07D239/88 , C07D401/12 , C07D401/04 , C07D401/06 , C07D403/12
CPC分类号： C07D403/12 , A61K31/505 , C07D239/88 , C07D239/91 , C07D239/96 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04
摘要： The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N.

10. 发明公开

EP1812004A1 ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS 有权
标题翻译： ORTHO CONDENSED吡啶和PYRIDIMIDIN衍生物（例如嘌呤）作为蛋白激酶抑制剂
公开(公告)号：EP1812004A1
公开(公告)日：2007-08-01
申请号：EP05797685.4
申请日：2005-10-25
申请人： Astex Therapeutics Limited , THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL , Cancer Research Technology Limited
发明人： BERDINI, Valerio , BOYLE, Robert George , SAXTY, Gordon , WALKER, David Winter , WOODHEAD, Steven John , WYATT, Paul Graham , CALDWELL, John , COLLINS, Ian , DA FONSECA, Tatiana Faria , DONALD, Alastair
IPC分类号： A61K31/52 , A61K31/519 , C07D473/34 , A61K31/437 , C07D471/04 , C07D487/04
CPC分类号： C07D471/04 , A61K31/4545 , A61K31/519 , A61K31/52 , A61K31/522 , C07D473/34 , C07D487/04
摘要： The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; Jl-J2 is N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q1 is a bond or a saturated C1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRq or NRqCO where Rq is hydrogen or methyl, or Rq is a C1-4 alkylene chain linked to R1 or a carbon atom of Q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Q2 is other than a bond; G is hydrogen, NR2R3, OH or SH provided that when E is aryl or heteroaryl and Q2 is a bond, then G is hydrogen; R1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R1 is hydrogen and G is NR2R3, then Q2 is a bond; and R2, R3, R4, R6 and R8 are as defined in the claims.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式